Clinical trial
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic…
NCT00098670 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00098670 |
|---|---|
| Title | Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia |
| Official title | A Phase II Study of Fludarabine + Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) Administered Subcutaneously as Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | alemtuzumab, rituximab, fludarabine phosphate |
| Enrollment | 102 |
| Start date | Oct 1, 2004 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Dec 8, 2004 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: